MyFinsight
Home
Blog
About
Contact
Download
Download image
Accrued liabilities
$413K
Accounts payable
$269K
Non-cash operating lease
expense
$83K
Stock-based compensation
$64K
Depreciation and
amortization
$34K
Interest expense on
related party note...
$33K
Change in inventory
reserve
$8K
Net cash provided by
operating activities
$121K
Canceled cashflow
$783K
Net (decrease)
increase in cash
-$60K
Canceled cashflow
$121K
Inventories
$264K
Net loss
-$220K
Prepaid expenses and
other current assets
$135K
Operating lease
liabilities
-$96K
Accounts receivable
$68K
Product sales
$2,315K
Net cash used in
financing activities
-$150K
Net cash used in
investing activities
-$31K
Loss from operations
-$190K
Total other expense,
net
-$30K
Canceled cashflow
$2,315K
Payments on related party
note payable
$150K
Purchases of property and
equipment
$23K
Payments for patent
licenses
$8K
Total operating
expenses
$2,505K
General and
administrative
$1,122K
Cost of sales
$954K
Selling and marketing
$273K
Research and development
$156K
Back
Back
Cash Flow
International Stem Cell CORP (ISCO)
International Stem Cell CORP (ISCO)
source: myfinsight.com